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Abstract 
Purpose: Survivors of breast cancer (BC) on the non-dominant side have more persistent deficits than those with 
cancer on the dominant limb. What is not known is whether those with BC use their involved upper limbs more, 
less, or at the same level as women without BC. Accelerometer use offers a quantifiable method to measure activity 
levels of upper limbs. The purpose of this study was to quantify the activity levels of the non-dominant involved 
limb among survivors of BC, and compare these values to their dominant limb, as well as the non-dominant limb of 
a control group. 
Methods: Participants (n=30) were women with unilateral BC on the non-dominant limb, diagnosed between 6 and 
24 months prior to data collection and a matched healthy group of women as controls. Participants completed the 
following questionnaires: medical and demographics, Brief Fatigue Inventory, Brief Pain Inventory – Short form, 
Disabilities of the Arm, Shoulder and Hand (DASH), and Beck Depression Index. Participants wore an 
accelerometer on each wrist during waking hours for seven days. Arm activity was measured using vector 
magnitude activity counts extracted from the accelerometers. 
Results: There was no significant differences in total vector magnitude activity counts between groups for either 
limb. Within group dominant to non-dominant comparison was significantly different (p≤0.001). No significant 
difference in pain was present but significant differences for fatigue (p=0.002), depression (p=0.004), and DASH 
scores (p=0.035) were present. 
Conclusions: Women with non-dominant BC use their involved limb similar to healthy controls but less than their 
dominant limb. 
Word count for abstract 250 with headings 
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A Quantitative Comparison of Arm Activity between Survivors of Breast Cancer and 
Healthy Controls: Use of Accelerometry 
Background and Purpose: 
Breast cancer (BC), the most commonly diagnosed cancer among women after skin 
cancer, was expected to affect more than 268,000 women in 2019 [1]. Over the last 25 years, 5-
year survival rates have increased to nearly 90% and it is estimated that over three million 
women are currently living with BC [1]. Therefore, as women are living beyond diagnosis and 
immediate treatment of BC, research is focusing on quality of life (QOL) issues and how long 
term deficits which negatively impact QOL can be mitigated. 
Survivorship begins at the point of diagnosis and extends throughout life after 
diagnosis [2,3]. Understanding how treatment can impact survivorship, both in terms of 
QOL and overall function, is important.  Lower levels of QOL post-treatment in survivors of 
BC may be attributed, in part, to activity limitations and participation restrictions which result 
from treatments for BC. Physical function scores on QOL scales decline the greatest immediately 
following surgical treatment for BC, but remain below baseline 6-104 weeks after treatment 
[4,5]. Treatments for BC including surgical management, chemotherapy, and radiation are 
associated with short term upper extremity functional morbidities including loss of motion [6-9], 
reduced strength [6,8,10], decline in functional abilities [11], and the development of secondary 
lymphedema [12]. These deficits are greater among women who undergo more involved 
interventions such as axillary lymph node dissection and mastectomies, and/or axillary radiation, 
than the less invasive lumpectomy and/or sentinel lymph node biopsy [13,14]. Furthermore, in a 





































































Research examining the long-term functional status of survivors of BC has shown that 
deficits in motion and strength persist beyond the time expected for normal recovery. Range of 
motion deficits continued for more than 5 years in 34% of survivors of BC after diagnosis [15], 
with two studies reporting the amount of loss exceeding 25° flexion and abduction motion in 
up to 38% of survivors of BC 2-4 years after surgery [16,17]. Strength deficits are often self-
reported, but in a study of 131 survivors of BC one year following surgery, an 8% loss in 
shoulder abduction strength measured by hand-held dynamometry was documented compared to 
pre-operative status [18]. In another study of 75 women who underwent both mastectomy and 
axillary lymph node dissection with axillary radiation with a mean time since surgery of 15 
months, flexion and abduction strength loss was 7 and 18% respectively [19]. Many studies 
do not report which limb, the dominant or the non-dominant, is impacted by breast cancer 
treatments, despite recording whether the right or the left side is involved.  Even in the 
studies which do report dominance, no separate analyses were conducted based on the 
dominance [19,20,21]. The preponderance of studies that lack detail about which limb is 
impacted by breast cancer treatments have the potential to overlook the role of dominance 
in recovery of upper extremity function. Yet, some important evidence shows that women 
who had BC on their non-dominant side have more persistent deficits than those who 
experienced cancer on the dominant limb. In a study examining 54 women on average four years 
post diagnosis of unilateral BC, range of motion, strength and self-reported function were 
measured and compared to the respective limb in a group of women without breast cancer.  
That is to say, the dominant involved limb of those with breast cancer was compared to the 
dominant limb of women without breast cancer, and the non-dominant involved limb of 



































































cancer. The significant findings from this study showed differences between those with 
cancer on their non-dominant side compared to women with cancer on the dominant side.  
Importantly, those with cancer on their non-dominant limb had greater deficits in motion, 
strength, and self-reported function on the Disabilities of the Shoulder, Arm and Hand (DASH) 
than women who did not [22]. It is unclear why the deficits are greater on the non-dominant 
involved limb. The greater impairments and disability for those whose cancer was on the 
non-dominant side may exist in part because forced usage is expected on the dominant limb, 
while the non-dominant limb may not be engaged in the same level of activity as the dominant 
side. This premise that women with cancer on their non-dominant limb use their involved limb 
less overall needs to be further investigated. 
The use of activity trackers or accelerometers is offering objective and quantifiable 
methods to measure the amount of activity in which upper limbs are engaged. Acuna and 
Karduna [23] established, in a study of 21 workers wearing an accelerometer for a day, that the 
amount of activity measured by the device was strongly correlated with the amount of dynamic 
activity in which the workers participated (r=0.81-0.97, p<0.01). Other research confirmed the 
ability of accelerometers to measure activity at different velocities. In a study examining how 
well accelerometers can detect motion, 30 participants wore an accelerometer during 
rehabilitation exercises performed at different velocities, while completing tasks mirroring 
activities of daily living. The accelerometer was sensitive enough to detect motion at different 
velocities (p<0.03), and correlated with visual activity counts for the activities of daily living 
(r=.93, p<0.01) [24].
In order to measure the amount of activity between limbs, accelerometers must be 




































































use on the dominant and non-dominant limbs as well as differences between the involved limb 
and a control group, 15 participants who were to undergo shoulder arthroplasty and 15 matched 
controls wore accelerometers for 3 days. Findings from this study revealed both significant 
differences between limbs in the experimental group (p<0.001), as well as differences between 
the involved limb of the experimental group and the controls (p=0.03) [25]. These results support 
similar findings in a study validating the use of accelerometry against a handedness 
questionnaire. Forty participants wore accelerometers on both limbs for 24 hours, and a 
significant correlation was found between the activity counts of the accelerometers and the 
handedness questionnaire [26].  
The need to measure limb use among women who experienced BC on their non-dominant 
side is important in order to proactively educate women about arm use after BC treatment in 
order to mitigate long term deficits. The Prospective Surveillance Model of BC care advocates 
for ongoing post-treatment monitoring of functional status in order to prevent morbidities 
associated with BC treatments or initiate rehabilitation before impairments impact 
function in a more substantial manner [27]. Accelerometry offers a method to objectively 
quantify upper extremity activity among survivors of BC. Currently, the authors are unaware of 
any evidence of using accelerometers to quantify upper extremity use in survivors of BC, 
therefore the primary purpose of this study is to measure bilateral upper extremity activity among 
women with BC and a control group. The primary hypothesis of this study is that the non-
dominant involved upper extremity activity of the women treated for BC will be lower than a 
control group. The secondary hypothesis is that non-dominant limb activity will be lower than 





































































 The study recruited thirty women (15 women with unilateral BC on their non-dominant 
side and 15 healthy controls) ages 30-69 years between May 2014 - September 2016. Women 
with BC were included if they (1) had unilateral cancer stage 0-3, (2) underwent surgical 
treatment for breast cancer, (3) had cancer on the non-dominant side, and (4) the cancer 
diagnosis was between 6 months and 24 months prior to data collection. The healthy control 
group had no history of BC. Exclusion criteria included: (1) any history of shoulder pathology in 
the last 6 months other than related to BC; (2) any shoulder, neck, or thoracic surgery; (3) 
bilateral cancer, or (5) women with BC who were still currently undergoing BC chemotherapy 
or radiation treatment. 
Study Design and Procedures 
 This investigation utilized a matched, case-control study design. This study was a multi-
centered study with the primary location at the University of Dayton Department of Physical 
Therapy, Dayton, Ohio, and the secondary location at Baptist Health Lexington, in Lexington, 
Kentucky. Approval was obtained by the Institutional Review Boards at both the University of 
Dayton and Baptist Health Lexington prior to initiating the study. After completing informed 
consent, participants completed five questionnaires including a medical history with 
demographics; fatigue; pain; depression; and arm function. 
Medical and Demographics Questionnaire 
 Participants provided information regarding age, arm dominance, type/stage of cancer, 
cancer treatment including type and date of surgery, radiation, and chemotherapy, duration 
since diagnosis/treatment initiation, occupational work demand, and shoulder activity level by 
self-report. Occupational work demand was rated sedentary, light, medium, heavy, and very 




































































activity level was measured using ratings of how much lifting, carrying, and overhead 
manipulation occurred on a regular basis. These self-reported activity levels were used to 
determine overall total self-reported activity. Investigators measured and recorded weight (in 
kilograms) and height (in meters) of each participant. 
Fatigue: Brief Fatigue Inventory 
 This 9-item questionnaire is designed to assess the severity and impact of cancer-related 
fatigue on daily functional activity in the previous 24 hours. The time required to complete this 
scale is approximately 5 minutes. This scale has a reported Cronbach alpha reliability ranging 
from 0.82-0.97 [29], and is highly recommended by the Oncology Evidence Database to Guide 
Effectiveness (EDGE) Taskforce for use with survivors of BC [30]. 
Pain: Brief Pain Inventory – Short form 
 This 11-item questionnaire is designed to assess the severity and interference of pain on 
daily functional activity in the previous 24 hours. The time required to complete this scale is 
approximately 5 minutes. This scale has a reported Cronbach alpha reliability ranging from 0.77-
0.91 [31], and is highly recommended by the Oncology Evidence Database to Guide 
Effectiveness (EDGE) Taskforce for use with survivors of BC [32].  
Depression: Beck Depression Index 
 This 21-item questionnaire measures characteristic attitudes and symptoms of depression 
for use in multiple populations. The time required to complete this scale is approximately 10 
minutes. This scale has a reported internal consistency (Cronbach alpha) ranging from 0.73-0.92 
[33].  




































































 This is a reliable and valid 30-item self-report scale scored 0 to 100, with higher scores 
indicating greater disability [34]. This scale has been used frequently to assess arm disability and 
function among women with breast cancer and is highly recommended by the Oncology 
Evidence Database to Guide Effectiveness (EDGE) Taskforce for use with survivors of BC [35].  
Quantification of Arm Activity 
Participants wore an activity tracker, or accelerometer, on each wrist during waking hours 
(6:00 am – 10:30 pm) for seven days. The ActiGraph GT3X+ (Actigraph, Corp., Pensacola, FL) 
activity monitor is a tri-axial accelerometer with a mass of 19 grams and physical dimensions of 
4.6 cm x 3.3 cm x 1.5 cm. The ActiGraph GT3X+ has the ability to record several measures but 
only the vector magnitude physical activity counts (VMPAC) were used in this study. The 
ActiGraph GT3X+ was set to record physical activity in the x, y, and z axes every 10 
seconds. This activity tracker was worn during all daily activities but was discouraged during 
bathing or activities including water. At the completion of the seven-day period, participants 
returned to the lab to turn in the accelerometers. Data from the accelerometers were downloaded 
to a computer for further analysis using ActiLife software (Actigraph Corp., Pensacola, FL).  
The average hourly VMPAC was calculated by summing the total VMPAC for the waking 
hours, divided by the total waking hours.  The average hourly VMPAC was used in 
analysis. 
Statistical Analysis 
 Group demographics were analyzed with descriptive statistics and independent samples t-
tests for age, body mass, activity level, and self-report questionnaires (Brief Fatigue Inventory, 
Brief Pain Inventory, Beck Depression, and DASH). Activity counts were compared between 




































































activity levels and fatigue, pain, depression, and self-reported function, a correlation 
analysis using Pearson r was conducted. The level of significance was set a priori at p <0.05. 
Results 
 Groups were similar across all domains of age, body mass, and total self-reported arm 
function (p>0.05). Women with BC were on average 10.5 (1-21) months from surgery. Table 1 
details participant demographics. 
 Independent samples t-test comparisons between groups for the self-report questionnaires 
revealed statistically significant differences between survivors of BC and control groups on three 
measures. Survivors of BC had higher levels of fatigue (p=0.002), depression (p=0.004) and 
scores on the DASH (p=0.035) than women without cancer. No significant differences were 
detected in pain levels between groups (p=0.085-0.156). Mean levels of self-reported outcomes 
are detailed in Table 2. 
 Vector magnitude physical activity counts were significantly different between limbs, but 
not between groups. Survivors of BC did not use either the involved non-dominant limb or the 
non-involved dominant limb any differently than women without BC (p=0.350 and p=0.334, 
respectively). Both groups showed significantly less use of the non-dominant limb compared to 
the dominate limb (p≤0.001). See Table 3. No relationship between VMPAC and levels of 
fatigue, pain, depression or self-reported function (p>0.05) was found. 
Discussion 
 To our knowledge, this was the first study examining quantity of arm motion of women 
treated for BC using accelerometry. Results indicate that women with BC appear to use their 
limbs at levels comparable to women without BC, in contrast to our hypothesis that this group of 




































































hypothesis that the non-dominant limb would demonstrate lower activity levels than the 
dominant limb was substantiated. This group of women with cancer on their non-dominant side 
used this non-dominant limb less than their dominant limb. This finding is consistent with the 
group of women without BC, and with other studies examining the effect of dominance on limb 
use [25].  
 Cancer-related fatigue (CRF) is the most common side effect of cancer treatment, and 
prevalence ranges between 58% and 94% for women with breast cancer during treatment, 
with overall prevalence reported at 48% throughout the survivorship continuum [36]. The 
participants in this study demonstrated greater levels of fatigue and depression than their control 
counterparts. Studies investigating CRF also report that depression is associated with CRF, and 
together, CRF and depression can result in lower levels of QOL [37,38]. In a secondary 
analysis of the women with BC in this study, depression was strongly correlated with 
fatigue (p<0.001, r=0.768), consistent with other research findings.  In those diagnosed with 
CRF, lower levels of physical activity are also reported [39]. Our results do not demonstrate a 
relationship between arm activity level and fatigue (p>0.05). It is possible that the results 
related to arm activity in this study do not show a difference with a control group because we 
matched our groups based on occupational and self-reported arm activity levels. 
Women with BC on their non-dominant limb have higher levels of self-reported 
disability, and less range of motion and strength than survivors of BC with involvement of their 
dominant limbs [22]. In this study, 60% of women had a mastectomy and/or axillary lymph node 
dissection, and over half underwent axillary radiation. These treatments typically result in greater 
disability than a lumpectomy or sentinel node biopsy. It is possible that the typically occurring 




































































women who have BC on the dominant limb. With DASH scores significantly greater among 
women with BC compared to the control group in this study, return to full function 
appears incomplete. This finding is important to understand within the context of prospective 
surveillance education. Rehabilitation specialists should be attentive to encouraging higher levels 
of usage of this limb, and should monitor impairment more closely, in order to regain pre-
treatment levels of functional use of the involved limb. 
 The DASH questionnaire scores among the survivors of BC group are higher than the 
control group, indicating some level of disability. It is important to understand the context of 
these findings. The DASH questionnaire is not limb specific. The published directions are to 
assess the level of difficulty completing common daily activities [34]. Some questions/activities 
are general such as preparing a meal, pushing open a door, carrying items, while other activities 
do imply use of dominant limbs. These activities include opening a jar, handling keys, writing 
and using a knife, and most of these activities are dominant driven. The groups of women in this 
study continue to report deficits despite no involvement of the dominant limb and this suggests 
an important role of the non-dominant limb in all activities. It is possible that supportive actions, 
such as stabilizing a jar when opening it, or securing food when using a knife, impact overall 
upper extremity function. This would need to be more closely examined. 
Limitations 
 This study does present several limitations. This population of survivors of BC focused 
only on those with non-dominant involvement and did not include women with cancer on the 
dominant side. How the activity levels in this population of women compare to survivors of BC 
with cancer on the dominant side is not known. Secondly, accelerometers are limited to 




































































well as the frequency the arms are lifted overhead cannot be determined. Inertial measurement 
units are becoming more available and may allow for more specific motions to be examined in 
the future. If the magnitude of motion could be captured, these findings may provide specific 
information for recovery of function. Lastly, only one participant had reconstruction. This single 
participant’s data did not result in any outliers, and reconstruction was >12 months prior to data 
collection. What is not captured in this study is the potential differences in function among 
women with reconstruction. This may be especially relevant as the current standard of care has 
evolved to reconstruction at the time of mastectomy, before healing of the cancer surgery has 
taken place.  
Conclusion 
This population of breast cancer survivors and controls use the non-dominant involved arm less 
than the dominant arm. This could hinder recovery efforts among women with BC on their non-
dominant limb compared to women who have BC on the dominant limb. In prospective 
surveillance education, rehabilitation specialists should be attentive to encouraging higher levels 
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Table 1. Demographic Characteristics - Mean (SD) 
Breast Cancer (n = 15) Control (n = 15) p value 
Age (years) 55 (10) 54 (9) 0.763 
Body Mass Index (kg/m2) 30.22 (4.41) 27.89 (6.44) 0.259 
Activity Level 13.77 (3.11) 14.67 (3.70) 0.497 
Months from diagnosis  10.5 (4.7) - - 
Type of Surgery Lumpectomy = 5  
Mastectomy = 4 
Lumpectomy + ALND = 3 
Mastectomy + ALND = 2 
- - 
Axillary Radiation 
 n = 8 - - 
Table 2. Self-Report Measures - Means  (SD) 
Outcome measure Breast cancer ( n=15) Healthy Control (n=15) p value 
DASH 21.57 (24.91) 4.94 (9.58) 0.035* 
Fatigue 3.52 (2.17) 1.24 (1.44) 0.002* 
Pain Severity 3.27 (2.11) 1.73 (1.81) 0.085 
Pain Interference 2.32 (2.54) 1.06 (1.52) 0.156 
Beck Depression 11.69 (7.07) 3.27 (2.76) 0.004* 
DASH Disability of Arm Shoulder and Hand Questionnaire; BFI Brief Fatigue Inventory; BPI severity Brief 
Pain Inventory short form severity; BPI interference Brief Pain Inventory short form interference; Beck 
Depression Inventory ; * α significant at the p<0.05 level 
Table 3. Arm Activity – Means (SD) 
Breast cancer (n=15) Controls (n=15) p value 
VMPAC Dominant 138,187 (35945) 151,461 (37990) 0.334 
VMPAC Non-
Dominant 
115,123 (31143) 127,214 (38148) 0.350 
p value ≤0.001* ≤0.001* 
VPMAC = vector magnitude physical activity counts; * α significant at the p<0.05 level 
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